Composition for the treatment of disease

ABSTRACT

A composition for use in the treatment of a condition or disorder related to mucosal barrier dysfunction in the gut, the composition comprising activated carbon. The condition may be, for example, pouchitis or proctitis.

The invention relates to a pharmaceutical composition comprisingactivated carbon particles for the treatment of conditions and disordersrelated to mucosal barrier dysfunction in the gut (gastrointestinaltract), including proctitis (e.g. radiation proctitis), and/orpouchitis.

BACKGROUND

The main patophysiologic driver of many gastrointestinaldisorders/diseases has been postulated to be translocation, i.e. mucosalbarrier dysfunction meaning that the gastrointestinal mucosa becomesleaky and substances that in normal situations should be kept in thelumen of the gut may pass across the gut epithelium into the body.Crohn's disease, ulcerative colitis, and IBS (irritable bowel syndrome)are examples of diseases in which clear evidence exists that the mucosaintegrity is diminished. In patients who have undergone resection of theentire colon and rectum an ileal pouch is constructed in order toreplace rectum and provide patients the possibility of more normal bowelhabits. The mucosa in this pouch has been shown to leak which may inducean inflammation in the pouch mucosa, known as pouchitis. In peritonitisdeveloping in patients with liver cirrhosis and ascites it has beenhypothesized that the bacteria generating the peritonitis actuallyoriginates from the gut and are transported to the peritoneal cavitydirectly through the gut mucosa. Radiation enteritis is induced byradiation therapy and it is believed that the radiation induced mucosaldamage disrupts the mucosa, thus allowing for translocation of chemicalsas well as bacteria and residues thereof.

It is not known which substances actually leak and are deleterious tothe body, although it is plausible to assume that everything that is notactively absorbed in one way or another may be harmful to the body. Suchsubstances include bacteria and viruses, residues of bacteria (LPS),bile acids (unless they have been actively absorbed and properly handledby the epithelial cells), toxins produced by bacteria, and foodsubstances that should not be absorbed.

Treatment of the conditions mentioned above has so far been focused onthe complications induced by the translocation, such as inflammation,infection, diarrhea induced dehydration, etc. Much effort in researchhas been devoted to find treatments to strengthen the mucosal barrier,yet without any significant progress. Another treatment modality is totake care of the potential lethal substances before they enter the gutlumen or within the gut lumen before they enter the gut mucosa. Theabsolutely most successful drug globally today is therefore pure waterwhich prevents people from getting cholera and other diseasestransmitted via decontaminated water. However, most of the abovementioned conditions/diseases are obviously not due to decontaminatedwater and thus require other treatment modalities.

Proctitis may be defined as an isolated inflammation of the anorectalarea (e.g. the anus and the lining of the rectum, generally affectingonly the last 6 inches of the rectum).

There are many causes of proctitis, but they can generally be grouped inthe following categories: Autoimmune disease; Harmful substances andradiation; Non-sexually transmitted infection; and Sexually transmitteddisease (STD).

Proctitis caused by STD is common among those who engage in analintercourse. STDs that can cause proctitis include HIV, gonorrhea,herpes, chlamydia, and lymphogranuloma venereum. Non-sexuallytransmitted infections causing proctitis are seen less often than STDproctitis. The classical example of non-sexually transmitted infectionoccurs in children and is caused by the same bacteria that cause strepthroat. Autoimmune proctitis is associated with diseases such asulcerative colitis or Crohn's disease. Proctitis may also be caused bycertain medications and inserting harmful substances into the rectum.

In addition, proctitis may also be linked to stress and ^([)can resultfrom an intolerance to gluten (celiac disease-associated “proctitis”)

Symptoms associated with proctitis are e.g. ineffectual straining toempty the bowels, diarrhea, rectal bleeding and possible discharge, afeeling of not having adequately emptied the bowels, involuntary spasmsand cramping during bowel movements, left-sided abdominal pain, passageof mucus through the rectum, and anorectal pain. A common symptom is acontinual urgency. Another is tenderness and mild irritation in therectum and anal region. A serious symptom is pus and blood in thedischarge, accompanied by cramps and pain during the bowel movement. Ifthere is severe bleeding, a condition called anemia can also be caused,showing symptoms such as pale skin, irritability, weakness, dizziness,brittle nails, and shortness of breath. Proctitis symptoms can beshort-lived or become chronic (last for weeks or months or longer) andare associated with great discomfort, reducing the patients qualitylife.

Radiation proctitis is inflammation and damage to the lower parts of thecolon and rectum after exposure to x-rays or other ionizing radiation asa part of radiation therapy. Radiation proctitis most commonly occursafter treatment for cancers such as cervical cancer, prostate cancer,and colon cancer.

Radiation proctitis can generally be classified as acute or chronic,usually delineated by the timeframe of symptoms in relation to thetreatment as well as the presenting symptoms and signs. in acuteradiation proctitis, the symptoms occur in the first few weeks aftertherapy. These symptoms include diarrhea and the urgent need todefecate, often with inability to do so (tenesmus). Acute radiationproctitis usually resolves without treatment after several months, butsymptoms may improve with butyrate enemas. This acute phase is due todirect damage of the lining (epithelium) of the colon. In chronicradiation proctitis the symptoms may begin as early as several monthsafter therapy but occasionally not until several years later. Thesesymptoms include diarrhea, rectal bleeding, painful defecation, andintestinal blockage. Intestinal blockage is a result of narrowing of therectum which blocks the flow of feces. Chronic radiation proctitisoccurs in part because of damage to the blood vessels which supply therectum, depriving the rectum of oxygen and necessary nutrients.Proctitis can be diagnosed by looking inside the rectum with aproctoscope or a sigmoidoscope.

Treatment for proctitis varies depending on severity and cause. Forexample for proctitis caused by bacterial infection antibiotics may beused. If the proctitis is caused by Crohn's disease or ulcerativecolitis, 5-aminosalicyclic acid (5-ASA) or corticosteroids may beapplied directly to the area in enema or suppository form, or takenorally in pill. Symptoms of radiation proctitis such as diarrhea andpainful defecation may be treated with oral opioids and stool softeners,respectively. Complications such as obstruction may require surgery.Several other methods were under development as of 2005 to lessen theeffects of radiation proctitis. These include sucralfate, hyperbaricoxygen therapy, corticosteroids, metronidazole, argon plasmacoagulation, and radiofrequency ablation. However, medical therapy isoften unsuccessful and surgery may eventually be required.

Accordingly, there is a need for additional treatment options either asan alternative treatment or a treatment supplementing current availabletherapies.

Pouchitis may be defined as inflammation of an ileal pouch (e.g. anartificial rectum surgically created out of ileal gut tissue in patientswho have undergone e.g. colectomy). Ileal pouch-anal anastomosis (IPAA)with proctocolectomy is a surgical treatment which may be used inpatients with ulcerative colitis where medical treatment is noteffective. A proctocolectomy is performed and the remaining ileum ismade into a reservoir, or pouch, which is connected to the anus. IPAAavoids a permanent ileostomy and means that the patient can retain stool(in the pouch) and eliminate this in the usual manner, thus improvingpatient quality of life. However complications can occur. One suchcomplication is pouchitis which is an inflammation of the lining ofpouch. Patients with pouchitis may suffer from diarrhoea, abdominalpain, cramps, increased number of bowel movements and a strong feelingof the need to have a bowel movement and pelvic discomfort.

There is presently no approved treatment or cure for pouchitis. Firstline treatment is usually with antibiotics, for example ciprofloxacinand metronidazole. Administration of antibiotics over a prolonged periodcan cause various side effects limiting their use. However, pouchitisdoes not always respond to antibiotic treatment. Indeed, pouchitis canbe classified based on the response to antibiotic treatment, and theclassifications include antibiotic-responsive pouchitis,antibiotic-dependent pouchitis, and antibiotic refractory pouchitis.

Other therapies include the use of probiotic or drugs used to control anepisode of pouchitis and their uses depends on the severity of the flareup. The drugs may be delivered using enemas applied directly into thepouch through the anus or may be given as tablets, or liquids taken bymouth.

In some cases pouchitis becomes chronic and does not respond totreatment and thus it may become necessary to perform another surgicaloperation. This may be to divert stool away from the pouch, to allow thepouch to rest, or in some severe cases to remove the pouch completely.

There is, therefore, a need for a composition which will treat pouchitisalongside, or as an alternative to, antibiotic or other currenttreatment therapies.

Activated carbon has been proposed for use in the treatment ofpouchitis. US2009/0148538 discloses oral administration of activatedcarbon to treat pouchitis.

However, orally administered activated carbon must pass through apatient's entire digestive system before it reaches the rectal regionand in doing so a large (and unpredictable) proportion of the carbonwill have adsorbed various chemicals and lost its activity, or otherwiselost its activity, depending on various factors such as amount of foodin gut, inter patient variations and day to day variations. Byincreasing the dose of orally administered activated carbon it may bepossible to increase the proportion of carbon that reaches the rectum inan activated state. However, activated carbon absorbs many essentialchemicals and nutrients on passing through the patient's digestivesystem and the long-term administration of large oral doses of activatedcarbon over a prolonged period is therefore undesirable and even harmfulto the patient.

Activated carbon has been prepared for rectal administration (e.g. as anenema) by pre-mixing to form a suspension with a liquid (e.g. propyleneglycol). The problem with such suspensions is that the carbon may loseits activity very quickly due to adsorption of components of the liquidby the activated carbon. For example, experiments have compared theamount of phenazone adsorbed per 100 g activated carbon suspended ineither water or 50% water/propylene glycol. The results showed that inwater, activated carbon adsorbed 43 g phenazone per 100 g carbon; in 50%propylene activated carbon adsorbed only 16 g per 100 g phenazone.Clearly, the activity of the carbon is markedly reduced by adsorption ofthe propylene glycol. Suspensions of activated carbon, therefore, needto be used shortly after preparation and have little practicalshelf-life.

Activated carbon has also been coated or otherwise formulated to allowit to pass through a patient's digestive system when taken orally. Forexample, U.S. Pat. No. 5,554,370 discloses capsules for oraladministration of activated carbon. It may be difficult to prepare acoating that accurately dissolves to release the activated carbon onlyonce it has passed into a patient's rectum. Furthermore, such coating orencapsulation may itself reduce or eliminate the activity of the carbon(e.g. in the same manner as described above for suspensions) and therebymay reduce the effectiveness of such coated particles.

JP2005-089306 discloses a suppository comprising activated carbon. Thesuppository is formulated with other excipients (e.g. gelatine, wax suchas Witepsol W35) which effectively coat the activated carbon. Asdiscussed above, coating reduces or eliminates the activity of thecarbon and thereby may reduce the effectiveness of such coatedparticles. Further, suppositories which include activated carbon may notachieve predictable or effective administration of activated carbonparticles for several reasons. Firstly, administration by suppositoryrequires effective insertion by the patient to the required depth, whichis not always achieved, and may be unhygienic. Further, therapeuticbenefit requires effective capillary flow of activated carbon particlesfrom the rectal cavity which may not be achieved because of the weightof the activated carbon particles and/or inter-patient variation ofmucosal secretion; the activated carbon may remain at the base of therectum and therefore not reach the site of activity. Thus, suppositoriesincluding activated carbon are far from ideal. JP2005-089306 alsodiscloses an example of an enema formulation. However, as indicatedabove, enema suspensions tend to have poor shelf life and reducedactivity due to adsorption of components of the liquid by the activatedcarbon. The inclusion of preservatives in enema suspensions of activatedcarbon (e.g. suspensions in water) to enhance shelf life isinappropriate because the preservative would be adsorbed by theactivated carbon, thereby reducing activity of the activated carbon andleaving the water phase unprotected.

Thus, there is a need for compositions for (use in) the treatment ofpouchitis and proctitis which retain their pharmaceutical activity priorto administration (i.e. have good shelf life), have improved handlingqualities, and are associated with predictable and repeatable dosing andgood patient compliance.

The applicants have surprisingly found that it is possible to formulateand administer activated carbon which is dust free [for exampleactivated carbon of particle size 0.02 to 1 mm, preferably of particlesize 0.05 to 1 mm (e.g in the form of “macroparticles” of particle sizefrom approximately 0.15 mm to 0.3 mm, e.g. 0.2 to 0.3 mm)], as a drypowder or dry dose. Formulation of activated carbon as a dry powderprevents deactivation of the carbon (there is no adsorption of otherexcipients or components of the administration vehicle on the activatedcarbon); allows effective administration without the problems associatedwith rectal suppositories and oral administration (particles of thissize may be administered rectally as a powder, and there is little or noloss of activity due to adsorption in the gut); and has other advantagesin terms of cleanliness and contamination (particles of this size arenot dusty).

According to the present invention there is provided a composition for(use in) the treatment of a condition or disorder related to mucosalbarrier dysfunction in the gut (gastrointestinal tract), the compositioncomprising activated carbon. The condition or disorder related tomucosal barrier dysfunction in the gut may be caused by translocation(i.e. caused by leaking in the gastrointestinal mucosa such thatsubstances that should remain in the lumen of the gut pass across thegut epithelium into the body). The condition or disorder related tomucosal barrier dysfunction in the gut may be proctitis (includingradiation proctitis), pouchitis, ulcerative colitis, Crohns disease,IBS, ascites (associated with liver cirrhosis), pancreatitis orradiation enteritis.

The composition comprising activated carbon may be for oraladministration and comprise:

-   -   (a) a core comprising activated carbon (e.g. activated carbon as        the sole active pharmaceutical ingredient);    -   (b) a first (e.g. an inner) layer around (e.g. surrounding) the        core, the first layer comprising an insoluble semipermeable        material; and    -   (c) a second (e.g. outer) layer around (e.g. surrounding) the        first layer which breaks down rapidly (dissolves) at a        predetermined pH (e.g. a layer which breaks down rapidly        (dissolves) at pH 5 to pH 7, e.g. a layer which breaks down        rapidly (dissolves) at pH 5, a layer which breaks down rapidly        (dissolves) at pH≧5.5, a layer which dissolves at pH 7 etc.)        and/or which dissolves at a predetermined location in the        gastrointestinal tract. The components (a), (b) and (c) may be        as described herein. The composition for oral administration may        be in the form of a powder, suspension, tablet, capsule etc.

The composition comprising activated carbon may be for rectaladministration and comprise a dry powder (a dry dose) of activatedcarbon of particle size 0.001 to 1 mm, for example 0.01 to 1 mm, forexample 0.02 to 1 mm.

According to the present invention in a first aspect, there is provideda composition (e.g. a pharmaceutical composition) for (or for use in)the treatment of proctitis (e.g. radiation proctitis), the compositioncomprising activated carbon. The composition may be for rectaladministration. The composition may be for oral administration.

According to the present invention in another aspect there is provided amethod of treatment of proctitis comprising a step of administering (toa subject in need thereof) a pharmaceutically effective amount of acomposition comprising activated carbon. The administration may be oralor rectal.

According to the present invention in one aspect, there is provided acomposition (e.g. a pharmaceutical composition) for use in the treatmentof proctitis, the composition comprising a dry powder (a dry dose) ofactivated carbon which is dust free. Preferably the dust free carbon isof particle size 0.02 to 1 mm, preferably of particle size 0.05 to 1 mm(e.g in the form of “macroparticles” of particle size from approximately0.15 mm to 0.3 mm, e.g. 0.2 to 0.3 mm).

According to the present invention in an aspect there is provided acomposition (e.g. a pharmaceutical composition) for use in the treatmentof proctitis, the composition comprising a dry powder (a dry dose) ofactivated carbon of particle size 0.001 to 1 mm, for example 0.01 to 1mm, for example 0.02 to 1 mm. Preferably, the activated carbon is ofparticle size 0.05 to 1 mm, for example 0.1 to 0.5 mm, for example 0.15mm to 0.4 mm, for example 0.2 to 0.3 mm. The activated carbon may be ofparticle size 0.15 to 1 mm. Preferably the activated carbon is ofaverage particle size 0.05 to 1 mm. Preferably the activated carbon isof average particle size 0.15 to 0.3 mm. Preferably the composition(e.g. pharmaceutical composition) is for use in the treatment ofradiation proctitis. Preferably the dry powder (dry dose) of activatedcarbon is free of dust or substantially free of dust.

According to the present invention in a further aspect there is provideda dry powder (a dry dose) of activated carbon of particle size 0.001 to1 mm, for example 0.02 to 1 mm, preferably 0.05 to 1 mm (for example 0.1to 0.5 mm, for example 0.15 mm to 0.4 mm, for example 0.2 to 0.3 mm) foruse in the treatment of proctitis, or for use in the manufacture of amedicament for the treatment of proctitis. The activated carbon may beof particle size 0.05 to 1 mm. Preferably the activated carbon is ofparticle size 0.15 to 0.3 mm. The activated carbon may be of averageparticle size 0.15 to 1 mm. Preferably the dry powder (dry dose) ofactivated carbon is free of dust or substantially free of dust.

According to the invention in an aspect there is provided a compositionfor use in the treatment of proctitis, the composition comprising a drypowder of activated carbon of particle size 0.001 to 1 mm, for example0.02 to 1 mm, preferably 0.05 to 1 mm, wherein the composition is foradministration (to be administered) rectally as a dry powder. Theactivated carbon may be of particle size 0.15 to 1 mm. The activatedcarbon may be of average particle size 0.15 mm to 0.3 mm.

According to the invention in an aspect there is provided a compositionfor use in the treatment of proctitis, the composition comprising a drypowder of activated carbon of particle size which is dust free, whereinthe composition is for administration (to be administered) rectally as adry powder. Preferably the dust free carbon is of particle size 0.02 to1 mm, preferably of particle size 0.05 to 1 mm (e.g in the form of“macroparticles” of particle size from approximately 0.15 mm to 0.3 mm,e.g. 0.2 to 0.3 mm).

The composition or dry dose may further comprise an antibiotic, ananti-inflammatory [e.g 5-aminosalicyclic acid (5-ASA)] or acorticosteroid and/or be for administration with an antibiotic, ananti-inflammatory [e.g 5-aminosalicyclic acid (5-ASA)] or acorticosteroid.

According to the present invention in another aspect there is provided amethod of treatment of proctitis comprising a step of administering (toa subject in need thereof) a pharmaceutically effective amount of acomposition comprising a dry powder (a dry dose) of activated carbon ofparticle size 0.001 to 1 mm, for example 0.02 to 1 mm, preferably 0.05to 1 mm (for example 0.1 to 0.5 mm, for example 0.15 mm to 0.4 mm, forexample 0.2 to 0.3 mm). The activated carbon may be of particle size0.15 to 1 mm. Preferably the activated carbon is of particle size 0.15to 0.3 mm. The method may further comprise administering (to a subjectin need thereof) a pharmaceutically effective amount of an antibiotic,5-aminosalicyclic acid (5-ASA) or corticosteroid. According to thepresent invention in another aspect, there is provided a composition(e.g. a pharmaceutical composition) for (or for use in) the treatment ofpouchitis, the composition comprising activated carbon. The compositionmay be for rectal administration. The composition may be for oraladministration.

According to the present invention in another aspect there is provided amethod of treatment of pouchitis comprising a step of administering (toa subject in need thereof) a pharmaceutically effective amount of acomposition comprising activated carbon. The administration may be oralor rectal.

According to the present invention in one aspect, there is provided acomposition (e.g. a pharmaceutical composition) for use in the treatmentof pouchitis, the composition comprising a dry powder (a dry dose) ofactivated carbon which is dust free. Preferably the dust free carbon isof particle size 0.02 to 1 mm, preferably of particle size 0.05 to 1 mm(e.g in the form of “macroparticles” of particle size from approximately0.15 mm to 0.3 mm, e.g. 0.2 to 0.3 mm). Preferably the composition isfor rectal administration.

According to the present invention in an aspect there is provided acomposition (e.g. a pharmaceutical composition) for use in the treatmentof pouchitis, the composition comprising a dry powder (a dry dose) ofactivated carbon of particle size 0.001 to 1 mm, for example 0.01 to1mm, for example 0.02 to 1mm. Preferably, the activated carbon is ofparticle size 0.05 to 1 mm, for example 0.1 to 0.5 mm, for example 0.15mm to 0.4 mm, for example 0.2 to 0.3 mm. The activated carbon may be ofparticle size 0.15 to 1 mm. Preferably the activated carbon is ofaverage particle size 0.05 to 1 mm. Preferably the activated carbon isof average particle size 0.15 to 0.3 mm. Preferably the dry powder (drydose) of activated carbon is free of dust or substantially free of dust.Preferably the composition is for rectal administration.

According to the present invention in a further aspect there is provideda dry powder (a dry dose) of activated carbon of particle size 0.001 to1 mm, for example 0.02 to 1 mm, preferably 0.05 to 1 mm (for example 0.1to 0.5 mm, for example 0.15 mm to 0.4 mm, for example 0.2 to 0.3 mm) foruse in the treatment of pouchitis, or for use in the manufacture of amedicament for the treatment of pouchitis. The activated carbon may beof particle size 0.05 to 1 mm. Preferably the activated carbon is ofparticle size 0.15 to 0.3 mm. The activated carbon may be of averageparticle size 0.15 to 1 mm. Preferably the dry powder (dry dose) ofactivated carbon is free of dust or substantially free of dust.

According to the invention in an aspect there is provided a compositionfor use in the treatment of pouchitis, the composition comprising a drypowder of activated carbon of particle size 0.001 to 1 mm, for example0.02 to 1 mm, preferably 0.05 to 1 mm, wherein the composition is foradministration (to be administered) rectally as a dry powder. Theactivated carbon may be of particle size 0.15 to 1 mm. The activatedcarbon may be of average particle size 0.15 mm to 0.3 mm.

According to the invention in an aspect there is provided a compositionfor use in the treatment of pouchitis, the composition comprising a drypowder of activated carbon of particle size which is dust free, whereinthe composition is for administration (to be administered) rectally as adry powder. Preferably the dust free carbon is of particle size 0.02 to1 mm, preferably of particle size 0.05 to 1 mm (e.g in the form of“macroparticles” of particle size from approximately 0.15 mm to 0.3 mm,e.g. 0.2 to 0.3 mm).

The composition or dry dose may further comprise an antibiotic orprobiotic and/or be for administration with an antibiotic or probiotic.

According to the present invention in another aspect there is provided amethod of treatment of pouchitis comprising a step of administering (toa subject in need thereof) a pharmaceutically effective amount of acomposition comprising a dry powder (a dry dose) of activated carbon ofparticle size 0.001 to 1 mm, for example 0.02 to 1 mm, preferably 0.05to 1 mm (for example 0.1 to 0.5 mm, for example 0.15 mm to 0.4 mm, forexample 0.2 to 0.3 mm). The activated carbon may be of particle size0.15 to 1 mm. Preferably the activated carbon is of particle size 0.15to 0.3 mm.

The method may further comprise administering (to a subject in needthereof) a pharmaceutically effective amount of an antibiotic or aprobiotic. In aspects of the invention, the composition (e.g.pharmaceutical composition) may comprise a dry powder (dry dose) ofactivated carbon. Herein the terms “dry dose” and “dry powder” ofactivated carbon mean activated carbon that has been maintained in dryconditions until the point of delivery to the patient's body. The use ofa dry powder (dry dose) of activated carbon particles means theadsorbtive capacity of the activated carbon is retained and maintaineduntil administration.

Preferably the composition or pharmaceutical composition is for rectaladministration. The composition or pharmaceutical composition maycomprise 450 μg to 10 g activated carbon (to treat pouchitis orproctitis). Preferably the composition or pharmaceutical compositioncomprises 450 μg to 5 g activated carbon. In an example, the compositionor pharmaceutical composition comprises 450 μg to 1 g activated carbon.In another example, the composition or pharmaceutical compositioncomprises 950 μg to 2.5 g activated carbon. In another example, thecomposition or pharmaceutical composition comprises 950 μg to 1.3 gactivated carbon. In an example the composition or pharmaceuticalcomposition comprises 1.2 g activated carbon. In an example thecomposition or pharmaceutical composition comprises 1.2 g (±10%)activated carbon. In other words, the composition or pharmaceuticalcomposition may comprise 1.08 to 1.32 g activated carbon.

The composition or pharmaceutical composition may comprise a dose (e.g.a unit dose or single dose) of 450 μg to 10 g activated carbon (to treatpouchitis or proctitis). Preferably the composition or pharmaceuticalcomposition comprises a dose (e.g. a unit dose or single dose) of 450 μgto 5 g activated carbon. In an example, the composition orpharmaceutical composition comprises a dose (e.g. a unit dose or singledose) of 450 μg to 1 g activated carbon. Doses of 450 μg to 1 gactivated carbon may be suitable for the treatment of children. Inanother example, the composition or pharmaceutical composition comprisesa dose (e.g. a unit dose or single dose) of 950 μg to 2.5 g activatedcarbon. In another example, the composition or pharmaceuticalcomposition comprises a dose (e.g. a unit dose or single dose) of 950 μgto 1.3 g activated carbon. Doses of 950 μg to 2.5 g (e.g. of 950 μg to1.3 g, e.g. doses of 1.1 g, 1.2 g etc.) activated carbon may be suitablefor the treatment of adults. Preferably the composition orpharmaceutical composition is for administration 1, 2, or 3 times a dayat the dose levels above. Preferably the composition or pharmaceuticalcomposition is for administration after the, or each, bowel movement.

The activated carbon may be granular activated carbon.

Herein the term “particle size” means the width at the narrowest pointof the activated carbon particle or granule (e.g the diameter for aspherical or roughly spherical particle).

Activated carbon (e.g. granular activated carbon) and its methods ofmanufacture is well known in the art and is available from, for example,Chemviron Carbon. Preferably the activated carbon is a pharmaceutical ormedical grade activated carbon.

Activated carbon is designated by sizes such as 8×20, 20×40, or 8×30. A20×40 carbon is made of particles that will pass through a U.S. StandardMesh Size No. 20 sieve (0.84 mm) (generally specified as 85% passing)but be retained on a U.S. Standard Mesh Size No. 40 sieve (0.42 mm)(generally specified as 95% retained). A U.S. Standard Mesh Size No. 50sieve has openings of 0.297 mm; a No. 60 sieve has openings 0.251 mm; aNo. 70 sieve has openings 0.211 mm; a No. 80 sieve has openings 0.178mm; a No. 100 sieve has openings 0.152; a No. 120 sieve has openings0.125 mm, a No. 140 sieve has openings 0.104 mm, and a No. 170 sieve hasopenings 0.089 mm. A notation for indicating particle size distributionusing mesh size is to use + and − designations. A “+” before the sievemesh indicates the particles are retained by the sieve, while a “−”before the sieve mesh indicates the particles pass through the sieve.This means that typically 90% or more of the particles will have meshsizes between the two values. Thus, if the particle size of a materialis described as −80/+170 (or could also be written −80+170), then 90% ormore of the material will pass through an 80 mesh sieve and be retainedby a 170 mesh sieve. Using the figures above, it can be seen that theresulting particles will have a range of diameters between 0.089 and0.178 mm (89 and 178 micrometers). The activated carbon may be ofparticle size distribution −50/+120, wherein 90% or more of theactivated carbon particles have diameter in the range from 0.125 mm to0.297 mm. Preferably the activated carbon is of particle sizedistribution −50/+100, wherein 90% or more of the activated carbonparticles have diameter in the range from 0.152 mm to 0.297 mm.Preferably the activated carbon is of particle size distribution−50/+80, wherein 90% or more of the activated carbon particles havediameter in the range from 0.178 mm to 0.297 mm. More preferably theactivated carbon is of particle size distribution −50/+70, wherein 90%or more of the activated carbon particles have diameter in the rangefrom 0.211 mm and 0.297 mm.

The activated carbon may be an activated carbon wherein 85% or more ofthe activated carbon particles have diameter in the range from 0.089 mmto 0.3 mm. The activated carbon may be activated carbon wherein 85% ormore of the activated carbon particles have diameter in the range from0.104 mm to 0.297 mm. The activated carbon may be activated carbonwherein 85% or more of the activated carbon particles have diameter inthe range from 0.125 mm to 0.297 mm. A particularly preferred activatedcarbon is activated carbon wherein 85% or more of the activated carbonparticles have diameter in the range from 0.152 mm to 0.297 mm.

It is preferred that the activated carbon particles are formed bygrinding carbon material to the desired size. Ground activated carbonhas an irregular particle shape and this irregular shape may beparticularly suited to being cleanly delivered (e.g. from a deliverydevice, as described herein). The activated carbon may be in the form ofspheronised or spherical particles. The activated carbon may be coated.

The (pharmaceutical composition) may be delivered into a patient'srectal cavity, e.g. using a device. One suitable device comprises arectally-insertable cannula having a proximal opening, a distal opening,and a cavity defined through a body of the cannula between the proximalopening and the distal opening for containing the dose of pharmaceuticalcomposition. An openable closure acts to close the proximal opening ofthe canula. Preferably, the cannula is of length 6 to 8 cm, e.g 7 cm.For example, a one-way valve may act to close the proximal opening ofthe cannula, or alternatively a suitable closure means such as afrangible seal that ruptures on the application of pressure may be used.A frangible seal, or similar ruptureable closure, could only be used onetime, and would need to be replaced if the cannula is to be re-used. Thedevice further comprises an actuation means for driving a volume offluid (e.g. liquid such as water, or gas such as air) through theone-way valve (or alternative closure means) and the cavity to flush thedose of pharmaceutical composition out of the cavity through the distalopening of the cannula. The actuation means or actuator may comprise asuitable volume of liquid or may be loadable with a suitable volume ofliquid for flushing the cavity. For example, the actuation means oractuator may have a chamber for holding a volume of liquid that may befilled with a suitable liquid prior to use of the device. A suitableliquid should be a liquid that does not influence the adsorptivecapacity of the carbon and may be water or a medical solution, forexample a saline solution. The skilled person will be aware of suitableliquids that can safely be injected into a patient's rectum. In anotherexample, the actuation means or actuator may comprise a suitable volumeof gas (e.g air) or may be loadable with a suitable volume of gas (e.g.air).

By containing the pharmaceutical composition within the cavity of thecannula, the activated carbon can be maintained separately from theliquid (if the fluid is a liquid) until the point of delivery; in otherwords the pharmaceutical composition is a dry dose or dry powder. As theactivated carbon (the pharmaceutical composition) is stored in a drycondition it does not lose its activity for a considerable period oftime and, therefore, the activity of the carbon particles is high asthey are injected into the patient. Preferably, the driving fluid ordriving liquid (if the fluid is a liquid) does not mix to a great extentwith the activated carbon during delivery but merely forces theactivated carbon out of the distal opening of the cannula and into apatient's rectum. The function of the fluid/liquid (e.g. air or water)is to act like a piston to drive the carbon into the patient, and theliquid/fluid may therefore be referred to as a driving liquid or apropellant.

Preferably, the medicament consists of particles of activated carbonhaving an average particle size greater than 0.05 mm. For example, ifthe particle size is determined by sieving a portion of powder through agraded series of sieves, the average particles size determined in thisway is preferably greater than 0.05 mm. If the average particle size islower than 0.05 mm then the medicament may be difficult to handle, as itwill be prone to forming an airborne dust. Such fine particles aredifficult to wet and may also clump or agglomerate during storage and,therefore, may not flush from the cannula easily. The applicant'sexperiments indicate that if fine particles having average particle sizelower than 0.05 mm are used, 20% to 50% of the particles (i.e. the dose)may be retained in the syringe and therefore not actually administered.

The applicants have found that if the activated carbon is of particlesize 0.15 mm to 1 mm, it is preferred that the fluid (driving fluid) isa liquid (e.g. water). The applicants have surprisingly found that ifthe activated carbon is of particle size 0.05 mm to 0.15 mm, the fluid(driving fluid) may be a liquid (e.g. water) or a gas (e.g. air).

In addition to the preferred particle size ranges stated above, it ispreferred that the activated carbon has a bulk density or apparentdensity of from 0.015 to 0.6 g/cm³, for example from 0.4 g/cm³ to 0.5g/cm³, preferably from 0.44 g/cm³ to 0.45 g/cm³. Bulk density may becalculated according to the standard procedure set out in ASTM D2854.The bulk density may be from 0.15 to 0.05 g/cm³.

The activated carbon particles are formed by grinding carbon material tothe desired size.

Loading the cannula with the pharmaceutical composition may be an actionundertaken by a patient. However, it may be convenient if the device ispreloaded with the pharmaceutical composition. The pharmaceuticalcomposition may, therefore, be loaded into the cannula cavity undercontrolled conditions and sealed at one end by the openable closure andat the other end by a sealing means. Such sealing means may, forexample, be a removable seal that is removed by the user before deliveryor a frangible seal that breaks on actuation. A suitable sealing meansmay be a cap or sheath that protects the external surface of thecannula, or at least of an insertable portion of the cannula. Thesealing means may even be a second one-way valve that allows passage ofthe contents of the cavity to pass out of the cannula when the device isactuated.

The actuation means may be a manually-operated actuator for example asyringe or a bellows or a bulb. The manually-operated actuator ispreferably capable of being filled with a driving liquid from a sourceof such liquid. For example, if the driving liquid is water then thewater may be supplied as sterile water for injection in a container,such as a flask or a vial, and then transferred to an actuation means,such as a syringe, prior to use of the device. It is preferable,therefore, that the actuation means is removably coupleable from thedevice to allow it to be filled or loaded with the driving liquid andthen coupled to the device in a suitable arrangement for forcing thedriving liquid through the one-way valve into the cannula cavity. It maybe advantageous for the actuation means to be an automatic actuator thatdelivers a volume of a driving liquid on, for example, the press of abutton. For example the actuation means may be a motorised actuator thatis operable to drive liquid from a source of liquid through the one-wayvalve and the cannula cavity to deliver the dose of particularpharmaceutical composition.

The device may comprise a flange or collar that extends radiallyoutwards from an external surface of the cannula at a predetermineddistance from the distal opening to determine the maximum depth ofinsertion of the cannula into the patient's rectum. Such a flange orcollar presents a physical barrier that prevents or hinders a portion ofthe cannula proximal to the flange or collar from easily being insertedthrough a patient's anus. The flange or collar may also help provide auser with purchase on the cannula to allow the application of insertionforce in the direction of a longitudinal axis of the cannula. Forexample, a user may apply a force on a proximal surface of a flange orcollar in order to insert the cannula to a depth at which a distalsurface of the flange or collar abuts the patient's anus.

The cannula may be preloaded with pharmaceutical composition in acontrolled environment. In such circumstances the loaded cannula may beconveniently supplied as a disposable component containing a preloadedvolume of pharmaceutical composition. Such a preloaded cannula could beattached to a device, the device could be activated to deliver thepharmaceutical composition, and then the spent cannula could be removedfrom the device and disposed of.

It may be convenient for a patient suffering from pouchitis or proctitisto be supplied with a kit of parts for treatment of the diseasecomprising a device as described above. Thus, a further aspect of theinvention may provide a kit for the treatment of pouchitis or proctitiscomprising a delivery device (e.g. as described above); a supply ofactivated carbon particles of particle size 0.001 to 1 mm, for example0.02 to 1 mm, preferably 0.05 to 1 mm (for example 0.1 to 0.5 mm, forexample 0.5 mm to 0.4 mm, for example 0.15 to 0.3 mm, for example 0.2 to0.3 mm); and optionally a source of fluid (e.g. liquid) for flushing theactivated carbon particles through the device. The activated carbon maybe of particle size 0.15 to 1 mm. The delivery device is preferably adevice for rectal delivery of activated carbon.

Preferably the activated carbon is of average particle size 0.15 to 0.3mm. A still further aspect of the invention may provide a kit for thetreatment of pouchitis or proctitis comprising a delivery device (e.g.as described above); a supply of activated carbon particles wherein 85%or more of the activated carbon particles have diameter in the rangefrom 0.089 mm to 0.3 mm (e.g. wherein 85% or more of the activatedcarbon particles have diameter in the range from 0.152 mm to 0.297 mm);and optionally a source of fluid (e.g. liquid) for flushing theactivated carbon particles through the device.

The fluid for flushing the activated carbon particles could be anysuitable liquid. Preferably the liquid is a liquid that does notinfluence the adsorptive properties of the activated carbon particlesand is safe for injection into a patient's rectum. The skilled personwill be aware of many such suitable liquids but as an example the liquidmay be sterile water, for example water for injection, a salt solution,etc. The fluid may be a gas (e.g. air).

As described above, it may be advantageous for the activated carbonparticles to be preloaded into disposable, rectally-insertable,cannulas. Thus, the invention may further provide a kit for thetreatment of pouchitis or proctitis comprising a disposable,rectally-insertable, cannula including (e.g. a single dose of) activatedcarbon particles of particle size 0.001 to 1 mm, for example 0.02 to 1mm, preferably 0.05 to 1 mm [for example 0.1 to 0.5 mm, for example 0.5mm to 0.4 mm, for example 0.2 to 0.3 mm]; and optionally an activationmeans that can be filled or loaded with a volume of driving fluid (e.g.liquid). The activated carbon may be of particle size 0.15 to 1 mm.Preferably the activated carbon is of average particle size 0.15 to 0.3mm.

The invention may further provide a kit for the treatment of pouchitisor proctitis comprising a disposable, rectally-insertable, cannulaincluding (e.g. a single dose of) activated carbon particles wherein 85%or more of the activated carbon particles have diameter in the rangefrom 0.089 mm to 0.3 mm (e.g. wherein 85% or more of the activatedcarbon particles have diameter in the range from 0.152 mm to 0.297 mm);and optionally an activation means that can be filled or loaded with avolume of driving fluid (e.g. liquid or gas such as air).

The disposable cannula may be removably-coupleable to the activationmeans such that the activation means is capable of driving a volume ofthe fluid (e.g. liquid) through the openable closure of the cannula andthe cannula cavity to flush the dose of activated carbon out of thecannula cavity through the distal opening of the cannula. The kit mayalso comprise a supply of the driving liquid/fluid. Preferably, the kitcomprises a plurality of rectally-insertable cannulas, each cannulabeing removably-coupleable to the activation means and each cannulabeing loaded with a single dose of activated carbon. Preferably theactivated carbon is of average particle size 0.15 to 0.3 mm.

The applicants have also developed a formulation comprising activatedcarbon for (use in) the treatment of a condition or disorder related tomucosal barrier dysfunction in the gut (gastrointestinal tract), fororal administration which retains, to a high degree, the adsorbtive(pharmaceutical) activity of activated carbon following oraladministration until it reaches the site of action, and/or whichminimises adsorbtion of essential chemicals and nutrients by theactivated carbon while passing through the patient's stomach etc. to thesite of action.

Thus, the composition (e.g.pharmaceutical composition) (for oral use)may comprise:

(a) a core comprising activated carbon (e.g. activated carbon as thesole active pharmaceutical ingredient);

(b) a first (e.g. an inner) layer around (e.g. surrounding) the core,the first layer comprising an insoluble semipermeable material; and

-   -   (c) a second (e.g. outer) layer around (e.g. surrounding) the        first layer which breaks down rapidly (dissolves) at a        predetermined pH (e.g. a layer which breaks down rapidly        (dissolves) at pH 5 to pH 7, e.g. a layer which breaks down        rapidly (dissolves) at pH 5, a layer which breaks down rapidly        (dissolves) at pH≧5.5, a layer which dissolves at pH 7 etc.)        and/or which dissolves at a predetermined location in the        gastrointestinal tract.

The composition for oral administration may be in the form of a powder,suspension, tablet, capsule etc.

The composition may be for treatment of a condition or disorder relatedto mucosal barrier dysfunction in the gut (gastrointestinal tract). Thecondition or disorder related to mucosal barrier dysfunction in the gutmay be caused by translocation (i.e. caused by leaking in thegastrointestinal mucosa such that substances that should be remain inthe lumen of the gut pass across the gut epithelium into the body). Thecondition or disorder related to mucosal barrier dysfunction in the gutmay be proctitis (including radiation proctitis), pouchitis, ulcerativecolitis, Crohns disease, IBS, ascites (associated with liver cirrhosis),pancreatitis or radiation enteritis.

The following discusses the components of the new compositions describedherein in more detail.

(b) The First Layer around the Core, the First Layer Comprising anInsoluble Semipermeable Material:

The first (e.g. an inner) layer may comprise an insoluble semipermeablemembrane.

Herein, the term “semipermeable” means that the material (layer) allows(e.g. gradual) diffusion of molecules and ions through the semipermeablematerial (layer) towards the core and into contact with the activatedcarbon and/or allows (e.g. gradual) diffusion of selected molecules andions through the semipermeable material (layer) towards the core andinto contact with the activated carbon. The (e.g. selected) moleculesand ions may be materials (e.g. toxins or local irritants) which provokeirritation in the gut (e.g. colon and/or rectum). The (e.g. selected)molecules/ions may be molecules/ions which are produced by the body. Thefirst (e.g. an inner) layer may comprise a material (a semipermeablemembrane) which allows (e.g. gradual) diffusion of molecules and ionsthrough the semipermeable material (layer) towards the core and intocontact with the activated carbon. Preferably, the (insolublesemipermeable) material does not substantially inactivate the activatedcarbon.

It will be appreciated that the material of the first layer may beselected based on the molecules and/or ions (e.g. substances whichcause, maintain, promote or exacerbate mucosal barrier dysfunction inthe gut, e.g. proctitis and/or pouchitis) which are to be adsorbed bythe activated carbon (and hence removed by excretion).

The first (e.g. inner) layer comprises an insoluble semipermeablematerial (e.g. a semipermeable membrane). In examples, the insolublesemipermeable material may be, for example, ethyl cellulose; apoly(meth)acrylate polymer such as EUDRAGIT® RL 100, EUDRAGIT® RL PO,EUDRAGIT® RL 30D, EUDRAGIT® RL 12.5, EUDRAGIT® RS 100, EUDRAGIT® RS PO,EUDRAGIT® RS 30D, EUDRAGIT® RS 12.5, EUDRAGIT® NE 30D, EUDRAGIT® NE 40D,all available from Evonik, glycerylmonostearate, cellulose acetatebutyrate, dipolylactic acid, polyvinyl chloride. The first (e.g. inner)layer may further comprise a water soluble material (e.g. a watersoluble polymer). The water soluble material (e.g. water solublepolymer) may be mixed with the insoluble semipermeable material (e.g.dispersed within the semipermerable material/membrane). In examples, thewater soluble material may be, for example sugar, PVA, PVP,hydroxypropylmethyl cellulose (HPMC), carboxymethylcellulose, sodiumcarboxymethyl cellulose, salts, sugar alcohols etc. The water solublematerial (e.g. water soluble polymer, e.g. HPMC) may be included in anamount which is 0.1 to 30% by weight of the amount of the insolublesemipermeable material (e.g. ethylcellulose) in the layer (b), forexample in an amount which is 2 to 25% by weight of the amount of theinsoluble semipermeable material (e.g. ethylcellulose) in the layer (b),for example 5 to 15% by weight of the amount of the insolublesemipermeable material in the layer, for example 10% by weight of theamount of the insoluble semipermeable material in the layer.

The water soluble material (e.g. water soluble polymer, e.g. HPMC) mayincrease the permeability of the insoluble semipermeable material (e.g.ethyl cellulose). For example, dissolution of the water soluble materiale.g. HPMC may form defects or channels in the ethyl cellulose coating,when the first layer is exposed after removal of the second (e.g.enteric) layer (see below), to thereby enable the adsorptive capacity ofthe activated carbon within the layer. Without being bound by theory, itis believed that the channels allow diffusion of material (e.g.substances which cause, maintain, promote or exacerbate mucosal barrierdysfunction in the gut, e.g. proctitis and/or pouchitis) across thefirst layer, so it may be adsorbed on the activated carbon. The rate ofdiffusion may therefore be controlled by the amount of water solublematerial (e.g. water soluble polymer, e.g. HPMC), and also the thicknessof the film; if the film is thinner, there will be a faster diffusion.

The thickness of the first layer around the core may correspond to atheoretical weight increase (of the core) from the layer (film coating)of 1 to 20%, for example 2 to 10%, for example 3 to 7%, for example 4%.It has been found that a coating of around this thickness provides aneffective adsorption capacity.

The first (e.g. inner) layer may consist essentially of the insolublesemipermeable material (e.g. ethyl cellulose) and the water solublematerial (e.g. water soluble polymer, e.g. HPMC). Avoiding the use ofsome other ingredients/excipients in the layer (b) prevents loss ofadsorptive capacity of the activated carbon to these excipients.

The insoluble semipermeable material may be an insoluble membrane whichincludes pores, for example a mixture of ethylcellulose with high- orlow viscosity HPMC (hydroxypropyl methylcellulose).

The first (e.g. an inner) layer may comprise a mixture of ethylcellulosewith high- or low viscosity HPMC (hydroxypropyl methylcellulose). Thefirst (e.g. an inner) layer may comprise a mixture of copolymerscomposed of 85 to 98% by weight free-radical polymerized C₁- to C₄-alkylesters of acrylic or methacrylic acid and 15 to 2% by weight (methy)acrylate monomers with a quaternary ammonium group in the alkyl radical.C₁- to C₄-alkyl esters of acrylic or methacrylic acid are methylmethacrylate, butyl methacrylate, methyl acrylate, ethyl acrylate, butylacrylate. A preferred (methy) acrylate monomer with a quaternaryammonium group is 2-trimethylammoniummethyl methacrylate chloride.

In other examples, the first (e.g. an inner) layer may comprise amixture of copolymers composed of 85 to 98% by weight free-radicalpolymerized C₁- to C₄-alkyl esters of acrylic or methacrylic acid and 15to 2% by weight (methy) acrylate monomers with a quaternary ammoniumgroup in the alkyl radical. C₁- to C₄-alkyl esters of acrylic ormethacrylic acid are methyl methacrylate, butyl methacrylate, methylacrylate, ethyl acrylate, butyl acrylate. A preferred (methy) acrylatemonomer with a quaternary ammonium group is 2-trimethylammoniummethylmethacrylate chloride.

The first layer may be a copolymer comprising 65% by weight methylmethacrylate, 30% by weight ethyl acrylate and 5% by weight2-trimethylammoniummethyl methacrylate chloride. Such copolymers arecommercially available and known as EUDRAGIT® RS type polymers, forexample EUDRAGIT® RS 100, EUDRAGIT® RS PO, EUDRAGIT® RS 30D, EUDRAGIT®RS 12.5 etc., available from Evonik Industries. Preferably, the firstlayer comprises EUDRAGIT® RS 30 D, available from Evonik Industries.

The first (e.g. an inner) layer may comprise a mixture of copolymerscomposed of 85 to less than 93% by weight free-radical polymerized C₁-to C₄-alkyl esters of acrylic or methacrylic acid and 15 to more than 7%by weight 2-trimethylammoniummethyl methacrylate chloride. The first(e.g. an inner) layer may comprise 50 to 70% by weight methylmethacrylate, and 20 to 40% by weight ethyl acrylate.

The first layer may be a copolymer comprising 60% by weight methylmethacrylate, 30% by weight ethyl acrylate and 10% by weight2-trimethylammoniummethyl methacrylate chloride. Such copolymers arecommercially available and known as EUDRAGIT® RL type polymers, forexample EUDRAGIT® RL 100, EUDRAGIT® RL PO, EUDRAGIT® RL 30D, EUDRAGIT®RL 12.5 etc., available from Evonik Industries. Preferably, the firstlayer comprises EUDRAGIT® RL 30 D, available from Evonik Industries.

Preferably, the first (e.g. inner) layer comprises a mixture of a firstcopolymer comprising 65% by weight methyl methacrylate, 30% by weightethyl acrylate and 5% by weight 2-trimethylammoniummethyl methacrylatechloride (EUDRAGIT® RS) and a second copolymer comprising 60% by weightmethyl methacrylate, 30% by weight ethyl acrylate and 10% by weight2-trimethylammoniummethyl methacrylate chloride (EUDRAGIT® RL).

The first layer may be EUDRAGIT® NE 30D or EUDRAGIT® NE 40D, availablefrom Evonik.

The amount of the first (e.g. an inner) layer may be 2 to 20% by weightbased on the weight of the core with the activated carbon.

(c) The Second Layer around the First Layer which Dissolves at aPredetermined pH and/or which Dissolves at a Predetermined Location inthe Gastrointestinal Tract:

The second (e.g. outer) layer prevents or reduces exposure of the firstlayer (and the activated carbon) to the digestive system environment,until a predetermined point in the digestive system after the stomach.The second (e.g. outer) layer may, for example, prevent or reduceexposure of the first layer (and the activated carbon) to the digestivesystem environment, until the composition reaches the lower part of theintestine, i.e. the late ileum, caecum and/or colon. The second layermay be selected from coatings which are pH-sensitive, redox-sensitive orsensitive to particular enzymes or bacteria. It will be appreciated thatthe mechanism of action of the compositions of the present invention(which holds the activated carbon within the inner membrane/layer) iscompletely opposite to controlled release formulations where an entericcoating is used to protect an inner layer (as it travels through thestomach) but then dissolves in the intestine to expose the inner layerwhich immediately releases the active pharmaceutical in the lowerdigestive tract.

The second layer may be a material which remains substantially intact(e.g. is highly stable, e.g. does not disintegrate or dissolve) at (e.g.highly) acidic pH found in the stomach (e.g. pH 1 to 3), but whichbreaks down rapidly (dissolves) at less acidic (more basic) pH, forexample at pH 5 to 7, e.g. pH≧5.5. Preferably the second (e.g. outer)layer is a pH sensitive polymer. The second (e.g. outer) layer may be apolymer which breaks down rapidly (dissolves) at a pH of about 5. Thesecond (e.g. outer) layer may be a polymer which breaks down rapidly(dissolves) at a pH of about 7. The amount of second (e.g. outer) layer(e.g. the enteric layer) may be 2 to 35% or even up to 50% w/w of thetotal composition, for example the amount of second (e.g. outer) layer(e.g. the enteric layer) may be 8 to 16% w/w of the total composition,for example 10 to 14% w/w of the total composition, for example 12% w/wof the total composition.

The thickness of the second (e.g. outer) layer (e.g. the enteric layer)around the core may correspond to a theoretical weight increase (of thecore and first layer) from the film coating of 4 to 16%, for example 6%to 14%, for example 8% or 12%. It was found that such a coating shouldensure passage of the stomach prior to exposure of the first layer.

Preferably the second (e.g. outer layer) is an enteric layer. Theenteric layer (enteric coating layer) prevents or reduces exposure ofthe first layer (and the activated carbon) to the digestive systemenvironment, until the composition reaches the small intestine (and evenafter the composition reaches the small intestine the semipermeablemembrane may minimise or prevent adsorption of beneficial substancessuch as nutrients by the activated carbon).

In some preferred examples, the layer(s) are chosen so the first (inner)layer is exposed in the small intestine, preferably close to the colon(to minimise adsorption of beneficial substances and reserve the bulk ofthe adsorptive capacity until the colon is reached). Preferably, theenteric layer is a material which remains substantially intact (ishighly stable) at (e.g. highly) acidic pH found in the stomach (e.g. pH1 to 3), but which breaks down rapidly (dissolves) at less acidic (morebasic) pH, for example at pH 5 to 7, e.g. pH 5.5, for example pH 7 asfound in small intestine. Preferably the enteric layer (enteric coatinglayer) is a pH sensitive polymer. The pH sensitive polymer may have afree acid group (carboxylic acid group) with dissolution caused bydeprotonation of the acid group. The enteric layer (enteric coatinglayer) may be a polymer which breaks down rapidly (dissolves) at a pH ofabout 5. The enteric layer (enteric coating layer) may be a polymerwhich breaks down rapidly (dissolves) at a pH of about 7. The entericlayer (enteric coating layer) may be a water soluble polymer. Theenteric layer may comprise one or more of a methyl acrylate-methacrylicacid copolymer, cellulose acetate succinate, hydroxy propyl methylcellulose phthalate, hydroxyl propyl methyl cellulose acetate succinate,polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acidcopolymer, sodium alginate and stearic acid. The enteric layer may be afatty acid, wax, shellac, plastics material etc. The enteric layer maybe a pH-dependent enterosoluble polymers, such as cellulose acetatetrimellitate (CAT), cellulose acetate phthalate (CAP), anioniccopolymers based on methylacrylate, methylmethacrylate and methacrylicacid, hydroxypropyl methylcellulose phthalate (HPMCP),hydroxypropylmethylcellulose acetate succinate (HPMCAS), methacrylicacid and ethyl acrylate copolymers, methacrylic acid and ethyl acrylatecopolymers, methacrylic acid and methyl methacrylate copolymers (1:1ratio), methacrylic acid and methyl methacrylate copolymers (1:2 ratio),Polyvinyl acetate phthalate (PVAP) and Shellac resins. The enteric layermay be EUDRAGIT® E100, E12.5 or E PO. The enteric layer may be, forexample, EUDRAGIT® L 100, EUDRAGIT® L 30D, a mixture of EUDRAGIT® S100/FS 30 D and EUDRAGIT® L 100 (see below). These EUDRAGIT® productsare available from Evonik Industries.

The enteric layer may comprise hydroxypropylmethylcellulose acetatesuccinate (HPMC AS), for example a HMPC AS which dissolves at pH between5.5 to 6.8. As is known in the art, it is possible to vary the contentof acetate and succinate in HPMC AS to provide an enteric coating whichdissolves from pH>5.5 to pH>6.8. The enteric layer may consist of, orconsist essentially of, hydroxypropylmethylcellulose acetate succinate(HPMC AS), for example a HMPC AS which dissolves at pH between 5.5 to6.8.

The amount of enteric layer may be 2 to 35% or even up to 50% w/w of thetotal composition, for example the amount of the enteric layer may be 8to 16% w/w of the total composition, for example 10 to 14% w/w of thetotal composition, for example 12% w/w of the total composition.

The thickness of the second (e.g. outer) layer (e.g. the enteric layer)around the core may correspond to a theoretical weight increase (of thecore and first layer) from the film coating of 4 to 16%, for example 6%to 14%, for example 8% or 12%. It was found from tests that such acoating should ensure passage of the stomach prior to exposure of thefirst layer.

The enteric layer (enteric coating layer) may comprise a copolymercomposed of 80 to 95% by weight free-radical polymerized C₁- to C₄-alkylesters of acrylic or methacrylic acid and 5 to 25% by weight(meth)acrylate monomers with an anionic group in the alkyl radical. C₁-to C₄-alkyl esters of acrylic or methacrylic acid are methylmethacrylate, ethyl methacrylate, butyl methacrylate, methyl acrylate,ethyl acrylate, butyl acrylate.

A (meth)acrylate monomer with an anionic group in the alkyl radical maybe, for example, acrylic acid or methacrylic acid.

The enteric layer may be a (meth)acrylate copolymer comprising 10 to 30%by weight methyl methacrylate, 50 to 70% by weight methyl acrylate and 5to 15% by weight methacrylic acid. Such polymers are commerciallyavailable and known as EUDRAGIT® FS type polymers. Preferably, theenteric layer comprises EUDRAGIT® FS 30 D, available from EvonikIndustries.

The enteric layer may be EUDRAGIT® E100, E12.5 or E PO. The entericlayer may be, for example, EUDRAGIT® L 100, EUDRAGIT® L 30D, a mixtureof EUDRAGIT® S 100/FS 30 D and EUDRAGIT® L 100 (see below). TheseEUDRAGIT® products are available from Evonik Industries.

The amount of the second (enteric) layer may be 5 to 15% by weight basedon the weight of the core with the activated carbon and the inner layer.

While not being limited by any theory, it will be appreciated thatexamples of the invention may work as follows. The outer (e.g. enteric)layer of the composition remains substantially intact at the acidic pHfound in the stomach (e.g. pH 1 to 3), and the pharmaceuticalcomposition therefore remains substantially intact as it travels to andthrough the stomach following oral administration. However, the outer(e.g. enteric) layer breaks down and dissolves at the pH found in thesmall intestine (e.g. pH 5 found in the upper part of the smallintestine, or pH 7 found in the lower part of the small intestine),thereby exposing the first (e.g. inner) layer. It should be noted thateven after the composition reaches the small intestine (and the entericlayer dissolves) the semipermeable membrane (in the first layer) mayminimise adsorption of beneficial substances such as nutrients by theactivated carbon. In some preferred examples, the layer(s) are chosen sothe first (inner) layer is exposed in the lower part of the smallintestine, preferably close to the colon (to minimise adsorption ofbeneficial substances and save the bulk of the adsorptive capacity forthe colon). The first layer comprises a material (e.g. a semipermeablemembrane) which may allow gradual diffusion of molecules and ions (e.g.substances which cause, maintain, promote or exacerbate mucosal barrierdysfunction in the gut, e.g. proctitis and/or pouchitis) through thesemipermeable membrane towards the core into contact with the activatedcarbon, where they are adsorbed. In some examples, dissolution of awater soluble material (e.g. HPMC) in the semipermeable material (e.g.ethyl cellulose) may form defects or channels in the semipermeablematerial/layer, when the first (e.g. inner) layer is exposed afterremoval of the second (e.g. enteric) layer, to thereby slowly enable theadsorptive capacity of the activated carbon within the layer. The(insoluble semipermeable) material does not substantially inactivate theactivated carbon, so the activated carbon is available to adsorb thesemolecules/ions. It will be appreciated that substantially all of theactivated carbon is held (remains) within the semipermeable membrane asthe composition (minus the outer layer) travels on through the digestivesystem (e.g. through the lower part of the small intestine and thecolon); the activated carbon is not released and is therefore less ableto remove (adsorb) essential chemicals such as nutrients.

It will be appreciated that inclusion of the semipermeable membrane (thefirst, inner, layer) may enable the adsorptive capacity of the activatedcarbon to be maintained as the composition travels through the wholelarge intestine [and the formulations may even retain some adsorptivecapacity even as they pass through the rectum and anus (i.e. thecompositions of the invention may still have adsorptive capacity whilethey are in the rectum or anus)]. If the semipermeable membrane/firstlayer were not present the removal of the outer (enteric) layer wouldmake all of the adsorptive capacity of the activated carbon available atonce (e.g. at the top of the small intestine), and the amount ofadsorptive activity remaining available by the time the compositionreached the large intestine may be insufficient to treat the medicalcondition.

Without wishing to be bound by theory, it is believed that molecules(e.g. substances which cause, maintain, promote or exacerbate mucosalbarrier dysfunction in the gut, e.g. proctitis and/or pouchitis) areable to diffuse through the semipermeable membrane where they areadsorbed by the activated carbon and then held on the carbon andsubsequently removed by excretion. It will be appreciated that themechanism of action of the compositions of the present invention (whichholds the activated carbon within the inner membrane/layer) iscompletely opposite to controlled release formulations where an entericcoating is used to protect an inner layer (as it travels through thestomach) but then dissolves in the intestine to expose the inner layerwhich immediately releases the active pharmaceutical in the lowerdigestive tract.

The applicants have found that the compositions of the invention mayprovide a more constant adsorption as they proceed through the gut(after removal of the enteric layer). The retention of adsorptivecapacity of activated carbon through the gut (even, depending on thecoating used, until the rectum or anus) is important because the exactlocation of the mucosal barrier dysfunction in the gut may not be known.

(a) A Core Comprising Activated Carbon

The core comprises activated carbon. Preferably the core consists of, orconsists essentially of, activated carbon. In other words, it ispreferred that the core is 100% activated carbon (i.e. activated carbonalone, without other excipients or active ingredients). Thus, preferablythe core does not include carrageenan (or a granulation enhancer etc.).The applicants have surprisingly found that it is possible to work withand coat individual granules of activated carbon (e.g. of specific sizeand/or hardness) without requirement for a granulation excipients suchas carrageenan.

The activated carbon is preferably sanded or deburred. Herein, the term“deburred” means untreated “raw” activated carbon is subjected to afinishing process to reduce or minimise the number of tips, peaks andedges (from the surface). The activated carbon may be deburred by theprocess described below. The active carbon may be deburred or sanded bycausing the untreated activated carbon particles to collide with eachother at high speed (e.g. speeds from 30 to 300 km/h, for example 35 to70 km/h). The burred or sanded activated carbon (of specific size) maythen be separated for use in/as core (a).

The activated carbon may include 0.9 or fewer tips peaks and edges ofheight 20-100 μm per particle or granule, for example 0.8 tips or fewerpeaks and edges per particle/granule, for example 0.6 tips peaks andedges or fewer per particle/granule.

The activated carbon may be, for example, of particle size 0.02 to 5 mm(depending on the raw material from which the activated carbon is made).The activated carbon may be, for example, of particle size 0.02 to 2.1mm, for example 0.05 to 2.1 mm, for example 0.1 to 2 mm, for example 0.2to 2 mm. The activated carbon may be of particle size from 0.6 to 1.2mm. The activated carbon of this particle size may be selected bysieving the activated carbon (e.g. after it has been sanded/deburred);by selecting activated carbon which includes particles that will passthrough a 1.2 mm sieve (i.e. a sieve having aperture size 1.2 mm) butwill not pass through a 0.6 mm sieve. Preferably the activated carbon isof particle size from 0.6 to 1.0 mm. The activated carbon of thisparticle size may be selected by sieving activated carbon (e.g. after ithas been sanded/deburred); the preferred activated carbon includesparticles that will pass through a 1.0 mm sieve (i.e. a sieve havingaperture size 1.0 mm) but will not pass through a 0.6 mm sieve. Hereinthe term “particle size” means the width at the narrowest point of theactivated carbon particle or granule (e.g the diameter for a sphericalor roughly spherical particle).

The activated carbon may be made from coconut shells.

Activated carbon (e.g. granular activated carbon) and its methods ofmanufacture is well known in the art and is available from, for example,Chemviron Carbon.

The applicants have found that activated carbon of particle size between0.6 to 1.2 mm (e.g. 0.6 to 1.0 mm) and/or which has been sanded ordeburred is ready to process (i.e. coat with the first layer); there isno need to granulate/process/extrude/spheronise the carbon or add agranulating agent such as carrageenan. This simplifies the process andmeans that each core has very high absorption capacity (the core is allactivated carbon and there are no excipients etc. present to “dilute”the adsorption capacity). Further, the deburring has the effect ofstabilising the adsorbtion rate. Sanding or deburring the raw activatedcarbon reduces the number of edges (per gram) on the surface of theactivated carbon. The raw material is itself very hard to coatconsistently, due to the roughness. If the particle is rough, there ishigh variation in coating thickness over the surface of the overallparticle, which has an effect on coating homogeneity and resultingexposure of adsorptive capacity prematurely (e.g. before the colon).Smoothing the activated carbon by sanding or deburring the surface meansthat the coating thickness is more consistent: the adsorptive capacityof activated carbon is provided in the appropriate place (e.g. in thecolon)

The activated carbon may be granular activated carbon. Preferably thecore is a granule of activated carbon. It is preferred that theactivated carbon particles/granules are formed by grinding or millingcarbon material to the desired size. Ground activated carbon has anirregular particle shape. The activated carbon may be in the form ofspheronised or spherical particles. The activated carbon may be coated.The activated carbon may be a pharmaceutical or medical grade activatedcarbon (e.g. activated carbon which complies with Ph. Eur., apart fromthe particle size).

Preferably the activated carbon is made from coconut shells.

It is preferred that the activated carbon is the sole activepharmaceutical ingredient. Further, it is preferred that the core doesnot include carrageenan.

According to the present invention in a further aspect there is providesa composition for use in the treatment of a condition or disorderrelated to mucosal barrier dysfunction in the gut (gastrointestinaltract), the composition being for oral administration and comprising:

(a) a core comprising activated carbon (e.g. activated carbon as thesole active pharmaceutical ingredient);

(b) a first (e.g. an inner) layer around (e.g. surrounding) the core,the first layer comprising an insoluble semipermeable material; and

(c) a second (e.g. outer) layer around (e.g. surrounding) the firstlayer which breaks down rapidly (dissolves) at a predetermined pH (e.g.a layer which breaks down rapidly (dissolves) at pH 5 to pH 7, e.g. alayer which breaks down rapidly (dissolves) at pH 5, a layer whichbreaks down rapidly (dissolves) at pH≧5.5, a layer which dissolves at pH7 etc.) and/or which dissolves at a predetermined location in thegastrointestinal tract. The components (a), (b) and (c) may be asdescribed herein.

The insoluble semipermeable material may be an insoluble membrane whichincludes pores, for example a mixture of ethylcellulose with high- orlow viscosity HPMC (hydroxypropyl methylcellulose).

The first (e.g. an inner) layer may comprise a mixture of ethylcellulosewith high- or low viscosity HPMC (hydroxypropyl methylcellulose).

The condition or disorder related to mucosal barrier dysfunction in thegut may be caused by translocation (i.e. caused by leaking in thegastrointestinal mucosa such that substances that should be remain inthe lumen of the gut pass across the gut epithelium into the body). Thecondition or disorder related to mucosal barrier dysfunction in the gutmay be proctitis (including radiation proctitis), pouchitis, ulcerativecolitis, Crohns disease, IBS, ascites (associated with liver cirrhosis),pancreatitis or radiation enteritis.

The composition for oral administration may be in the form of a powder,suspension, tablet, capsule etc.

According to the present invention in a further aspect there is providesa method of treatment of a condition or disorder related to mucosalbarrier dysfunction in the gut (gastrointestinal tract), the compositionbeing comprising a step of orally administering (to a subject in needthereof) an oral pharmaceutical composition comprising:

(a) a core comprising activated carbon (e.g. activated carbon as thesole active pharmaceutical ingredient);

(b) a first (e.g. an inner) layer around (e.g. surrounding) the core,the first layer comprising an insoluble semipermeable material; and

(c) a second (e.g. outer) layer around (e.g. surrounding) the firstlayer which breaks down rapidly (dissolves) at a predetermined pH (e.g.a layer which breaks down rapidly (dissolves) at pH 5 to pH 7, e.g. alayer which breaks down rapidly (dissolves) at pH 5, a layer whichbreaks down rapidly (dissolves) at pH≧5.5, a layer which dissolves at pH7 etc.) and/or which dissolves at a predetermined location in thegastrointestinal tract. The components (a), (b) and (c) may be asdescribed herein. The insoluble semipermeable material may be aninsoluble membrane which includes pores, for example a mixture ofethylcellulose with high- or low viscosity HPMC (hydroxypropylmethylcellulose).

The first (e.g. an inner) layer may comprise a mixture of ethylcellulosewith high- or low viscosity HPMC (hydroxypropyl methylcellulose).

The condition or disorder related to mucosal barrier dysfunction in thegut may be caused by translocation (i.e. caused by leaking in thegastrointestinal mucosa such that substances that should be remain inthe lumen of the gut pass across the gut epithelium into the body). Thecondition or disorder related to mucosal barrier dysfunction in the gutmay be proctitis (including radiation proctitis), pouchitis, ulcerativecolitis, Crohns disease, IBS, ascites (associated with liver cirrhosis),pancreatitis or radiation enteritis.

The orally administrable composition may be administered as a powder,suspension, tablet, capsule etc.

SPECIFIC EMBODIMENTS OF THE INVENTION

Specific embodiments of the invention will now be described withreference to the Figures in which:

FIG. 1 illustrates a device for delivering a dose of a pharmaceuticalcomposition for use in the treatment of pouchitis or proctitis accordingto an embodiment of the invention comprising activated carbon particles;

FIG. 2 illustrates a rectally-insertable cannula for use as a componentpart of the device illustrated in FIG. 1;

FIG. 3 illustrates a longitudinal cross-section of therectally-insertable cannula of FIG. 2;

FIG. 4 illustrates a kit of parts for the treatment of pouchitis andproctitis comprising a device according to the embodiment of FIG. 1 anda source of sterile water;

FIGS. 5 to 10 illustrate method steps involved in using the kit of FIG.4.

FIG. 1 illustrates a device 10 for delivering a dose of a pharmaceuticalcomposition comprising activated carbon particles into a patient'srectal cavity. The patient has been diagnosed with proctitis (orpouchitis) by a medical professional (e.g. doctor) and has been assessedas being suitable for, and likely to be responsive to, such treatment.The device comprises a rectally-insertable cannula 20, a syringe 30, anda length of flexible tubing 40 coupling the syringe 30 to the cannula20.

The cannula 20 is illustrated in greater detail in FIGS. 2 and 3. Thecannula 20 has a generally elongated shape and has a proximal end 25 anda distal end 26. A cavity 22 is defined within a body 23 of the cannula20, the cavity having a proximal opening 21 at the proximal end of thecannula leading into the cavity 22 and a distal opening 24 at the distalend of the cannula leading out of the cavity 22. The cavity 22 extendslongitudinally between the proximal opening 21 and the distal opening24.

The body 23 of the cannula 20 further defines a radially-extendingflange or collar 27, which extends around a circumference of the cannulabody 23 between the proximal end 25 and the distal end 26. A portion ofthe cannula body extending from the radially-extending flange toward theproximal end of the cannula may be termed a proximal portion 25 a of thecannula body 23. Likewise, a portion of the cannula body 23 extendingfrom the radially-extending flange 27 to the distal end 26 may be termeda distal portion 26 a of the cannula.

In the specific embodiment described herein, the cannula is formed as atwo-piece construction. Thus, the distal portion of the cannula body 26a and the proximal portion of the cannula body 25 a are formed asseparate polyethylene components and then joined together to form thecannula 20. The radially-extending flange is formed as part of theproximal portion of the cannula 25 a, but could clearly be formed aspart of the distal portion of the cannula 26 a. The cannula may also beformed as a single component.

The distal portion 26 a of the cannula is externally-sized and shaped tobe inserted through a human anus into a human rectum in order to deliverthe pharmaceutical composition into the patient's rectal ampulla.Accordingly, the distal portion 26 a has a length of 7 cm and has asubstantially circular external cross-section. The distal portion 26 ais tapered at an angle of about 2° and has an outer diameter of 6.5 mmat the distal end 26. The radially-extending flange 27 has asubstantially circular cross-section and a diameter of 3.0 cm. Theproximal portion 25 a of the cannula body 23 is also of substantiallycircular cross-section and tapers from an inner diameter of about 7.7 mm(outer diameter 15.5 mm) adjacent to the radially-extending flange to aninner diameter of about 6.3 mm (outer diameter 8.7 mm) at the proximalend 25 of the cannula.

The cavity 22 defined within the cannula body 23 extends longitudinallythrough the cannula body from the proximal end 25 to the distal end 26.At the distal end 26 the cavity terminates at the distal opening 24. Thedistal opening is of substantially circular cross-section and has adiameter of 2.8 mm. At the proximal end of the cannula the cavity 22 isspanned by a one-way valve (not shown). The diameter of the cannula atthe proximal end is 6.3 mm. The one-way valve 50 is actuatable to allowfluids (e.g. liquids) to enter the cavity 22 through the proximalopening 21 of the cannula, but does not allow the passage of materialcontained within the cavity 22 of the cannula out of the cavity throughthe proximal opening 21. The cavity is about 120 mm in total length fromthe proximal opening to the distal opening. The cavity has a maximumdiameter in the region of the radially-extending flange, where theinternal cavity diameter is 7.7 mm. The volume of the cavity is about2.6 cm³, and the cannula is designed to be loaded with about 1.2 gram orabout 1.3 gram of activated carbon particles having a bulk density ofabout 0.45 g/cm³.

An upper surface 27 a of the radially-extending flange 27 acts as a stopto prevent the cannula from being inserted too far into a patient'srectum. As the cannula is inserted to its maximum penetration depth, theupper surface 27 a of the radially-extending flange abuts the patient'sanus and prevents inadvertent over-penetration. It is clear that theradially-extending flange does not need to extend around the entirecircumference of the cannula in order to perform this function. Anyradially-extending projection that hinders passage of the cannulathrough the anus may be used if over-penetration is a concern.

A lower surface 27 b of the radially-extending flange 27 a may act as alug that allows a user to apply an insertion-force in the direction ofthe distal end 26 of the cannula to facilitate its insertion.

The proximal end 25 of the cannula body 23 defines an internal cavity 28in which a threaded linkage is pressed so as to allow the cannula to becoupled to a source of driving fluid (e.g. liquid). The thread iscompatible with luer fittings as are well known in the medicalprofession. Luer fittings are commonly used to attach tubing andsyringes and needles for medical use.

The internal surface of the cavity 22 is substantially cylindrical incross-section and does not comprise any sudden changes in cross-sectionin order to minimise turbulence when a liquid is forced through thecavity 22.

In use, a pharmaceutical composition comprising activated carbonparticles is contained within the cavity 22.

The pharmaceutical composition comprises about 1.2 g activated carbon(e.g. 1 g in Example 3 below) of average particle size 0.15 mm to 0.3 mmwherein 85% or more of the activated carbon particles have diameter inthe range from 0.152 mm to 0.297 mm. The activated carbon is obtainedfrom Chemviron Carbon tested to EUP 2010 Version 7.

The cavity 22 and the distal opening 24 are sized and shaped to optimisedelivery of activated carbon particles having an average particle sizeof between 0.15 mm and 0.3 mm. Particles of this size range are easierto handle compared with fine activated carbon particles previously usedfor medical treatments and do not stick or agglomerate within the cavityto a great extent, which would hinder their delivery. As the particlesare loaded within an elongated cavity that has a wide opening, the waterentering the cavity through the one-way valve effectively acts to pushthe particles out of this opening. Preferably the water does not mixwith the particles within the cavity (although some mixing isinevitable) but rather the front of the water entering through the valvepushes the cavity full of activated carbon particles ahead of it.

When loaded within the cavity 22, the activated carbon particles areprevented from escaping through the proximal opening 21 by means of theone-way valve 50 that spans the proximal opening. The distal opening 24may also be closed by a closure means in order to retain the particleswithin the cavity 22. For example, the device may comprise a removableseal or a frangible seal spanning the distal opening 24. Alternativelyor additionally, the device may comprise a cap that acts to close thedistal opening 24 and, thereby retain any pharmaceutical compositionwithin the cavity 22 until it is desired to use the device.

The cannula body is formed by an injection moulding process from amedical grade polyethylene. Polyethylene is a substantially inertmaterial that is commonly used in medical devices. It is noted that thecannula may be formed from any suitable medical material and that theperson skilled in the art would be aware of such material. For examplethe cannula may be made from a polyethylene, polupropylene or apolycarbonate or some other convenient medical grade polymer.

The syringe is a standard syringe having a liquid capacity of 12 ml, andcomprises a plunger 31 that is slidable within a barrel 32. The syringehas a threaded luer-type connection 33, which allows the syringe to becoupled to the flexible tubing 40. The syringe acts as an actuationmeans of the device for driving a volume of liquid through the cannulacavity 22 to flush a dose of pharmaceutical composition contained withinthe cannula cavity.

The flexible tubing 40 is formed from a flexible medical-grade polyvinylchloride (PVC) and has an internal diameter of 2.6 mm, a length of 45cm, and a capacity (i.e. the volume defined by the lumen of the tubing)of 2.4 ml. Each end of the flexible tubing terminates in a luer-typeconnection 41, 42. A first luer connection 41 allows the flexible tubingto be connected to the proximal end of the cannula 20 while a secondluer connection 42, at the opposite end of the flexible tubing to thefirst luer connection 41, allows the flexible tubing to be connected tothe syringe 30.

It may be particularly convenient to supply a patient with both thedevice and any further elements that they need to self-administer a doseof a pharmaceutical composition comprising activated carbon particles.Thus, it may be advantageous to supply component elements of a devicefor delivering a dose of pharmaceutical composition and other materialsin the form of a kit. An embodiment of such a kit is illustrated in FIG.4. This kit includes component parts of a device as described above,i.e. a rectally insertable cannula 20, a syringe 30, and a length offlexible tubing 40 for connecting the syringe to the cannula (theflexible tubing is shown connected to the cannula). The kit alsocomprises a container filled with water for injection 60. The water forinjection is used as a driving fluid to expel the pharmaceuticalcomposition through the cannula and into the patient.

The kit may comprise other components. For example, the kit may includea supply of activated carbon for loading into the cannula. The kit maycomprise a plurality of cannulas, each one pre-loaded with a dose ofactivated carbon.

In FIGS. 3 and 4, the cannula 20 is shown with its distal portion 26 asheathed within a cap 29. The cap comprises a stopper or bung 29 a and adownwardly depending sheath 29 b, and both sheaths the distal portion ofthe cannula 26 a and closes the distal opening 24 thereby retainingmedicament within the cannula.

The cannula is supplied pre-loaded with a pharmaceutical compositionconsisting of particles of activated carbon. The kit illustrated in FIG.4 may be used to deliver a dose of a pharmaceutical compositioncomprising activated carbon particles as described below.

FIGS. 5 to 10 illustrate a method of using the kit as illustrated inFIG. 4 in order to deliver a dose of activated carbon particles. Theindividual component parts of the kit are removed from packaging inwhich they are supplied and set out before the user. The plunger 31 ofthe syringe 30 is withdrawn to the 11 ml marking on the barrel 32 of thesyringe (as illustrated in FIG. 5). The user then removes a sealing cork61 that acts to seal the container of water for injection 60(illustrated in FIG. 6). The container of water 60 is maintained in anupright position so that its contents are not spilled.

The syringe 30 is coupled to the water container 60 in order to chargethe syringe with water. The threaded luer connection 33 of the syringeengages with a corresponding mating thread in the neck 62 of the watercontainer 60 (illustrated in FIG. 7).

The water container 60, with the syringe now affixed, is inverted(illustrated in FIG. 8). The plunger 31 of the syringe 30 is thendepressed to the 3 mm mark. This action causes air within the barrel ofthe syringe to be forced into the water container 60, which pressurisesthe container. The plunger is then withdrawn again. On withdrawal of theplunger, the water for injection passes into the barrel of the syringe.If required, the plunger can be repeatedly depressed and withdrawn.After these steps the barrel of the syringe should be filled with waterfor injection from the container of water 60 (this is illustrated inFIG. 9). Clearly, any technique for filling the syringe with the watermay be used.

The cannula 20, which is preloaded with the pharmaceutical compositionas described above, is coupled to the flexible tubing by screwing in theluer connections on the flexible tubing with equivalent connections onthe cannula. Likewise, the flexible tubing is also connected to thesyringe filled with water by coupling the luer connections on theflexible tubing and on the syringe (FIG. 10).

Immediately prior to use the cover or cap 29 is removed from the cannula20. This opens the distal opening 24 such that the pharmaceuticalcomposition can be forced out. If desired, the external surfaces of thedistal portion 26 a of the cannula may be lubricated, for example withpetroleum jelly. Such lubrication may improve a patient's comfort oninserting the cannula. In some embodiments the distal portion of thecannula may be pre-lubricated. The distal portion 26 a of the cannula 20is then inserted carefully through the patient's anus so that the distalend 26 and the distal opening 24 enter the patient's rectal cavity. Thecannula should be inserted until the radially-extending flange 27 abutsthe anus and prevents further insertion.

With the cannula in place, the plunger 31 of the syringe 30 is pressedquickly. The plunger should preferably travel to its full extent over aperiod of no longer than 2 seconds. The water for injection containedwithin the barrel of the syringe is forced out of the syringe andthrough the flexible tubing 40, through the one-way valve 50 that closesthe proximal opening 21 of the cannula and into the cannula cavity. Onentering the cannula cavity 22, the flow of water forces thepharmaceutical composition that is contained within the cavity out ofthe cavity through the distal opening 24 and into the patient's rectalcavity.

After delivery of the pharmaceutical composition the cannula is removedfrom the patient's rectum. The cannula may then be cleaned, if it is tobe re-used, or disposed of, if the device is only intended forone-time-use.

The device, kit, and method of using the device and kit as describedherein refer to a specific embodiment. It is clear that many factors maybe varied without changing the nature of the invention. For example, theembodiment described in detail above utilises a syringe as an actuationmeans for driving a volume of liquid through the cannula cavity. Anysuitable actuation means may be used instead. For example, it may bepossible to use a bellows or a bulb as an alternative to a syringe. Inparticular, it may be possible to replace the syringe with an automaticor motorised injection means for driving the volume of liquid.

The actual volume of liquid injected, and therefore the size of thesyringe, may be varied. For example, such variation may be desirable ifthe volume of the cannula cavity is larger or smaller than theembodiment described above, or if the length of flexible tubing islonger or shorter. The volume of liquid should be sufficient to drivethe entire contents of the cannula into the patient's rectum withoutdelivering an excessive volume of liquid to the patient.

Although the embodiment described above uses flexible tubing disposedbetween the syringe and the cannula, other embodiments may dispense withthe flexible tubing and provide a direct connection between the cannulaand syringe or other means for driving the volume of liquid.

The size and shape of the cannula may be varied from the dimensionsdescribed in the embodiment above. Different sized cannulas may, forexample, allow different volumes of pharmaceutical composition to bedispensed to a patient.

As set out above, the applicants have found that if the activated carbonis of particle size 0.15 mm to 1 mm, a liquid (e.g. water) should beused as driving fluid to deliver the dry powder. The applicants havesurprisingly found that if the activated carbon is of particle size 0.05mm to 0.15 mm, the fluid (driving fluid) may be either a liquid (e.g.water, as above) or a gas (e.g. air).

Herein, particle sizes are expressed, where appropriate, as the volumemean diameter (VMD). The volume mean diameter of the microparticles iswell known and is readily measured by techniques known in the art.

EXAMPLE 2 Oral Formulation

As set out above, it is possible to use an oral formulation to treatproctitis and pouchities. A suitable oral formulation is described asfollows.

Activated carbon particles made from coconut shells are milled down togranules of particle size 0.2 mm to 2.0 mm). These individual particles(granules) are each coated with an inner coating (insolublesemipermeable membrane) comprising a mixture of Eudragit RS 30 D andEudragit RL 30 D, which is applied by methods well known in the art(e.g. the methods of U.S. Pat. No. 6,632,454 B2). The individual coatedactivated carbon particles (granules) are then each coated with an outerenteric coating comprising Eudragit FS 30 D, again by methods well knownin the art (e.g. the methods of U.S. Pat. No. 6,632,454 B2), to providean oral formulation.

The oral formulation is suitable for oral administration e.g. as apowder or suspension to treat proctitis or pouchitis. In another examplethe coated particles (granules) may be formulated as a tablet or in acapsule.

EXAMPLE 2A The Components of the Oral Composition

The oral composition (e.g.pharmaceutical composition) of the inventioncomprises:

(a) a core comprising activated carbon (e.g. activated carbon as thesole active pharmaceutical ingredient);

(b) a first (e.g. an inner) layer around (e.g. surrounding) the core,the first layer comprising an insoluble semipermeable material; and

(c) a second (e.g. outer) layer around (e.g. surrounding) the firstlayer which breaks down rapidly (dissolves) at a predetermined pH (e.g.a layer which breaks down rapidly (dissolves) at pH 5 to pH 7) or whichdissolves at a predetermined location in the gastrointestinal tract.

The following deals with each layer in turn.

(a) A Core Comprising Activated Carbon Activated Carbon and itsProduction

To ensure the suitability of the activated carbon starting material forprocessing into a final uniform and reproducible product, the activatedcarbon starting material is subjected to a pre-treatment process. Theobjective of this pre-treatment is to reduce the number of burrs, tipsand sharp edges because these will negatively impact the quality of thefirst (and second) layers which are applied to the surface of theactivated carbon. A burr, tip or sharp edge is more difficult to coverwith a uniform layer of coating material, hence particles are subjectedto mechanical erosion to form a more uniform surface.

The starting material activated carbon is made from coconut shells

(Chemviron Carbon, Lockett Road, Ashton-ln-Makerfield, Lancashire WN48DE UK product name AQUACARB 607C 14×40 having a particle size from 1.40mm to 0.425 mm). The process mechanically erodes burrs, tips or edges onthe individual carbon particles by having them colliding with oneanother at high speed when passing through a collision tube, followed bya sieving process to achieve particles of adequate size distribution.After completing the erosion process, the collected particles are nowsubjected to a vibration sieve in portions of 200 g and sieved through a1.0 and subsequently a 0.6 mm sieve. The fraction passing the 1.0 mmsieve and not the 0.6 mm sieve has an acceptable particle size and shapeto be used as starting material for coating processes.

b) The First Layer around the Core, the First Layer Comprising anInsoluble Semipermeable Material:

It was a target to develop film compositions with a minimum of additives(especially for the inner film) to minimise take up of adsorptivecapacity by additives. The first (e.g. an inner) layer may thereforeconsist essentially of the insoluble semipermeable material (e.g. ethylcellulose) and (optionally) the water soluble material (e.g. HPMC).Avoiding other ingredients/excipients prevents loss of adsorptivecapacity of the activated carbon to these excipients. The simplest filmwould be an ethylcellulose film (insoluble semipermeable material alone)applied from an ethanol solution. It was expected that this film wouldbe very tight, not allowing sufficient/efficient passage of unwantedsubstances. Thus, to ensure that the adsorption capacity of activatedcarbon is made available/accessible, different water soluble materials(e.g. water soluble polymers) were mixed into the ethylcellulose to makeholes in it or make it dissolve (on exposure to the pH in the lowerintestine/colon). Polyvinylpyrrolidone (PVP), Hypromellose (HPMC) andPolyvinyl alcohol (PVA) were used as water soluble polymers. PVP is bothsoluble in water at ethanol, HPMC only in water. Low viscosity grades ofPVP and HPMC were chosen (Kollidon K30 and Pharmacoat 603 respectively)in order not to influence the coating process with highly viscous filmsolutions.

For the following examples, the film coating was performed by methodswell known in the art, in a GEA Aeromatic Fielder Strea 1 fluid-bedinstalled with a wurster tube. Liquid was pumped with a peristalticpump. As Hypromellose (HPMC) is not soluble in Ethanol andEthylcellulose is not soluble in water, the ethanol/water mix at whichboth polymers can dissolve was found to be between 70:30 and 80:20. Themix 75:25 was chosen as standard in the film (first layer) formulationswith Ethylcellulose combined with Hypromellose.

The first layer was added by the above methods, to provide compositionsaccording to the invention as set out in the Tables below.(c) The Second Layer around the First Layer which Dissolves aPredetermined pH and/or which Dissolves at a Predetermined Location inthe Gastrointestical Tract:

For the enteric coating, a polymer with release at higher pH wasselected, aiming at having the activated carbon available as close tothe colon as possible. On the other hand, choosing an enteric coatingwith release at a too high pH could mean that the activated carbon wouldnot be available in all patients (because gut pH and transit time canvary considerably from patient to patient and day to day). Based onthis, Aqoat HG (HPMC-AS; Hypromellose-Acetate-Succinate; releases at pH6.5) was chosen for the examples. Alternatives could be e.g. other Aqoatproducts (which release at other pH values), mixtures of Eudragit S100/FS 30 D and Eudragit L 100 to reduce the release from pH 7.0resulting from using Eudragit S 100/FS 30 D alone.

The amount of enteric layer in the following examples is 8 to 16% w/w ofthe total composition, for example 10 to 14% w/w of the totalcomposition, for example 12% w/w of the total composition.

For the following examples, the film coating was performed by methodswell known in the art, in a GEA Aeromatic Fielder Strea 1 fluid-bedinstalled with a wurster tube. Liquid was pumped with a peristalticpump.

The second layer was added by the above methods, to provide compositionsaccording to the invention as set out in the Tables below.

Production of Compositions of the Invention

Compositions according to the invention were made according to thefollowing Tables, in 300 g batches (i.e. 300 g activated carbon):

Batch Core First layer Second layer RD1202-19-C2 Activated carbon 90%ethylcellulose, Aquoat HG Sanded/deburred 10% HPMC Weight increaseWeight increase (thickness) 8% (thickness) 4% RD1202-22-C2 Activatedcarbon 90% ethylcellulose, Aquoat HG Sanded/deburred 10% HPMC Weightincrease Weight increase (thickness) 8% (thickness) 6% RD1202-23-C2Activated carbon 90% ethylcellulose, Aquoat HG Raw (not sanded) 10% HPMCWeight increase Weight increase (thickness) 8% (thickness) 4%

RD1202-19-C2 and RD1202-22-C2 are compositions of the invention and werebased on sanded/deburred activated carbon produced by the methoddescribed above. The purpose of the sanding process was to round thecorner of the activated carbon crystals to allow for the layers/films tocover the corners. Non-sanded activated carbon has very sharp and apexcorners which would be considered difficult to cover uniformly duringfilm coating. RD1202-23-C2 used raw and un-sanded activated carbon. Thesanded activated carbon for all batches was fractionated by particlesize and only the fraction 0.6 mm to 1.2 mm was used. However, it wassubsequently decided that the fraction 0.6 mm to 1.0 mm is preferred.

The first layer for the examples in the Table was 90% ethylycellulose,10% HPMC, and was applied in ethanol/water by the fim coating processdescribed above. The film coating processes all performed well in theSTREA fluid-bed without the need for adding plastizicer. Inlet airtemperature setpoint for the ethanol:water films was 33° C. Batches wereremoved after 4% (RD1202-19-C2, RD1202-23-C2) or 6% (RD1202-19-C2)theoretical weight increase.

The second enteric layer was applied to the first layer, also by methodsdescribed above. The enteric polymer was Hypromellose-Acetate-Succinate(HPMC-AS; Aqoat HG) dissolving at pH 6.5. Aqoat HG was designed fororganic coating (ethanol/water mixture) and can be applied without theaddition of plasticizers or lubricants. As the composition was alreadyfilm coated using organic coatings, organic coating was used. The secondlayer film was formulated as a 6% solution in ethanol/water 80:20 andapplied until 8% weight increase.

More information is given in the following Table:

Batch no RD1202-19 RD1202-22 RD1202-23 — Inner film Ethylcellulose 90%90% 90% — (Ethocel 7) Hypromellose (HPMC: 10% 10% 10% — Pharmacoat 603)Activated charcoal Sanded Sanded Raw Sanded % increase in weight  4%  6% 4% 0% Ethanol 96% 75% 75% 75% — Purified Water 25% 25% 25% — Batch noRD1202-19-C2 RD1202-22-C2 RD1202-23-C2 RD1202-24 Enteric coatHypromellose-AS 100% 100% 100% 100% (Aqoat HG) % increase in weight  8% 8%  8%  8% Ethanol 96%  80%  80%  80%  80% Purified Water  20%  20% 20%  20%

The oral formulation is suitable for oral administration e.g. as apowder or suspension to treat proctitis or pouchitis. In another examplethe coated particles (granules) may be formulated as a tablet or in acapsule.

EXAMPLE 3 Activated Charcoal as Treatment of Pouchitis or RadiationProctitis, a Pilot Study (Clinical Phase: II) Background:

The main patophysiologic driver of many gastrointestinaldisorders/diseases has been postulated to be translocation, i.e. thegastrointestinal mucosa has become leaky and substances that in normalsituations should be kept in the lumen of the gut may pass across thegut epithelium. For example, patients who have undergone an IPAA (IlealPouch Anal Anastomisis) may develop an inflammation in the pouch mucosa,or pouchitis. It has been postulated that the inflammation is due to adecreased barrier function of the pouch mucosa, thus allowing fortranslocation. Similarly, proctitis is believed to be due to decreasedbarrier function.

It is feasible to assume that the two mentioned conditions may act asmodels for several other diseases in which decreased mucosal barrierfunction has been suggested as a pathophysiologic mechanism.

Objective:

To demonstrate that treatment of pouchitis and/or radiation proctitiswith activated charcoal diminish the symptoms of the mucosalinflammation in these conditions.

The inclusion and exclusion criteria for the trial were as follows:

Inclusion: Male or female above 18 years of age

-   -   Acute pouchitis or Chronic Radiation Proctitis    -   If radiation proctitis radiation should have been directed        against the rectal area only    -   Willing to undergo endoscopic examination    -   Ongoing Inflammation as judged by investigator    -   Diagnosis verified by histopathology    -   No ongoing antibiotic treatment for the condition        Exclusion: Age below 18 years of age    -   Relapsing pouchitis    -   Signs of inflammation above the pouch    -   Radiation directed to other parts of the intestines

Background

The activated carbon was administered using the device described aboveand illustrated in the attached Figures.

The dose administered by the medical device in the trial was 1 g. Inorder to provide as much activated carbon to the affected areas aspossible the device was used twice daily (with at least 6 hours inbetween administrations); thus, the device was used to administeractivated carbon at a dose of 1 g twice daily. The duration of the trialwas 4 weeks.

The dose was administered by the patient in the morning: after breakfast(after defecation), and in the evening, prior to “going to bed”.

Endpoints

A reduction in the number of stools per day was selected as the primaryendpoint. Typically, a patient with proctitis or pouchitis will pass 10to 12 stools. Secondary endpoints were reduction in pouch mucosalinflammation as judged at endoscopy; reduction in inflammatory responseas judged by histopathology; reduction in severity of “urgency”;reduction in number of bloody stools; and reduction in severity ofabdominal cramping. The Investigational Medical Device (IMD) isillustrated in the the attached drawings (see especially FIGS. 1 and 4)and consisted of:

1. Rectal cannula seta. Rectal cannula with cap, valve and carbon chamberb. Connection tube with female connectorc. Vaseline plug (soft yellow paraffin/vaselinum flavum)d. Activated carbon 1.3 g (for injection into the rectum)2. Sterile water (Ph. Eur. Quality) 10 ml in plastic container3. Sterile syringe (CE-marked)—10 ml

All medical devices are provided by Nordic Drugs AB. Subjects weretrained in the use of the device (i.e. in the manner described abovewith reference to the Figures) by the investigator or a nurse. Theactivated carbon (Activated Carbon 610C (EUP 2010) was administeredusing 10 ml. sterile water (Fresenius Kabi) by means of a sterilesyringe (BRAUN Inkjet, CE marked), by the method described above.

All medicinal device components were handled according to the principlesof Good Manufacturing Practice and applicable ISO guidelines.

On day 1, consent was obtained and the patient instructed in how to usethe device. The investigator performed an overall assessment of thepatient's state of health in order to confirm eligibility.

1-27. (canceled)
 28. A method for treating a condition selected from thegroup consisting of proctitis, radiation proctitis, and pouchitis in asubject in need thereof, comprising administering to the subject aneffective amount of a composition comprising activated carbon, whereinthe method comprises rectally administering an effective amount of a drydose of a composition comprising particles of ground activated carbon.29. A method according to claim 28, wherein the activated carbon has aparticle size of from 0.001 to 1 mm.
 30. A method according to claim 28,wherein the activated carbon has a particle size of from 0.02 to 1 mm.31. A method according to claim 28, wherein the activated carbon has aparticle size of from 0.05 mm to 1 mm. (New) A method according to claim28, wherein the activated carbon has a particle size of from 0.02 to 5.0mm.
 33. A method according to claim 28, wherein the activated carbon hasa particle size of from 0.6 to 1.2 mm.
 34. A method according to claim28, wherein the activated carbon has an average particle size of from0.2 mm to 0.3 mm.
 35. A The method according to claim 28, wherein theactivated carbon has an average particle size of from 0.15 mm to 1 mm.36. A method according to claim 28, wherein the activated carbon has anaverage particle size of from 0.15 mm to 0.3 mm.
 37. A method accordingto claim 28, wherein the composition comprises from 450 μg to 10 gactivated carbon.
 38. A method according to claim 28, wherein theactivated carbon is the sole active pharmaceutical ingredient in saidcomposition.